Diopsys

Diopsys developed and commercialized advanced visual electrophysiology devices—specifically VEP and ERG systems—for early detection and management of a range of eye diseases. Their technology provides objective functional data on the visual system to aid diagnosis and monitor treatment efficacy. The company was recognized as a leader in modern visual electrophysiology before being acquired by LumiThera in November 2021[4][5].

Clinical results have shown that these tests can detect dysfunction up to eight years before permanent vision loss occurs for certain conditions such as glaucoma or diabetic retinopathy[5].

The company’s products are used both for rare diseases and common disorders affecting the retina or optic nerve.

No active clinical drug development pipeline; all programs are commercialized diagnostic devices.

Pipeline breadth reflects product lines rather than traditional drug programs.